Acrivon Therapeutics (NASDAQ:ACRV) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage set an “overweight” rating on the stock.

Several other research firms have also recently weighed in on ACRV. KeyCorp began coverage on shares of Acrivon Therapeutics in a report on Friday. They issued an “overweight” rating for the company. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Acrivon Therapeutics in a report on Thursday, November 14th. Finally, BMO Capital Markets dropped their target price on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Acrivon Therapeutics presently has an average rating of “Buy” and a consensus target price of $23.67.

Acrivon Therapeutics Trading Up 5.7 %

Shares of ACRV stock traded up $0.33 on Friday, hitting $6.12. The stock had a trading volume of 5,632 shares, compared to its average volume of 35,487. Acrivon Therapeutics has a twelve month low of $3.19 and a twelve month high of $11.90. The company has a fifty day moving average price of $6.35 and a two-hundred day moving average price of $7.35. The firm has a market cap of $190.58 million, a P/E ratio of -2.27 and a beta of 0.77.

Hedge Funds Weigh In On Acrivon Therapeutics

Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new stake in Acrivon Therapeutics during the 4th quarter worth approximately $40,000. Dimensional Fund Advisors LP bought a new stake in shares of Acrivon Therapeutics in the second quarter worth $58,000. Barclays PLC increased its holdings in Acrivon Therapeutics by 51.2% in the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after purchasing an additional 11,273 shares during the period. JPMorgan Chase & Co. lifted its stake in Acrivon Therapeutics by 548.3% in the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after buying an additional 28,748 shares during the period. Finally, Exome Asset Management LLC acquired a new stake in Acrivon Therapeutics in the third quarter worth $817,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.